Kanghong Pharmaceutical approves all resolutions at 2024 AGM

Chengdu Kanghong Pharmaceutical Group (SZSE:002773) announced the successful passage of all resolutions at its 2024 Annual General Meeting (AGM), held on May 21, 2025. Key resolutions included the approval of the 2024 Board of Directors' report, the 2024 Supervisory Board report, the 2024 financial statements, and the 2024 annual report and its summary. Shareholders also approved the proposed 2024 profit distribution plan and a special report on the company's use of raised funds, the 2025 financial budget, and the re-appointment of the auditing firm. Additionally, shareholders approved the use of company funds for investments and changes to the company's registered capital. All resolutions were approved by significant majorities, with no resolutions rejected. The company's legal counsel confirmed the meeting's procedures and resolutions' validity.